|
Cardiovascular Exchange Summit 2011
|
|
|
Definitions
|
|
|
Global Burden of Obesity
|
|
|
Trends in adult obesity from around the world
|
|
|
Type 2 Diabetes (T2DM)
|
|
|
Obesity and Type 2 Diabetes
|
|
|
Diabetes and Weight Loss
|
|
|
The Need to Feed
|
|
|
NICE clinical guideline 43
|
|
|
Treatment options
|
|
|
BARIATRIC SURGERY NICE GUIDELINES (CG43)
|
|
|
Dieting vs. Bariatric Surgery
|
|
|
Procedures
|
|
|
Types of Bariatric Surgery
|
|
|
Percent of excess weight lost post-surgery
|
|
|
Health Benefits of Bariatric Surgery
|
|
|
Resolution of co-morbidities
|
|
|
Risks of Bariatric Surgery
|
|
|
Nutritional Deficiencies
|
|
|
Effect of operation on DM
|
|
|
T2DM & Bariatric Surgery
|
|
|
Metabolic Surgery
|
|
|
Roux-en Y Gastric Bypass (RYGBP) ‘Gold standard’
|
|
|
|
Gut hormones control body weight& blood sugar
|
|
|
Ghrelin: a unique orexigenic hormone
|
|
|
Ghrelin stimulates hunger and food intake in normal-weight volunteers
|
|
|
Obese subjects have reduced ghrelin levels
|
|
|
Peptide YY (PYY)
|
|
|
Obese humans and mice have low circulating levels of PYY
|
|
|
Glucagon-like peptide 1 (GLP-1)
|
|
|
Liraglutide
|
|
|
Liraglutide
|
|
|
Increased food availability
|
|
|
PYY3-36 modulates homeostatic and reward regions
|
|
|
Ghrelin modulates neuronal activity in homeostatic and reward regions
|
|
|
Role of ghrelin in obesity
|
|
|
PYY and Dieting
|
|
|
|
|
|
Ghrelin and Bariatric Surgery
|
|
|
Gastric bypass surgery reduces hunger and increases satiety
|
|
|
Study Design
|
|
|
Anthropometric Data
|
|
|
Appetite Ratings
|
|
|
Changes in PYY post-RYGB
|
|
|
Changes in GLP-1 post-RYGB
|
|
|
Changes in acyl-ghrelin post-RYGB
|
|
|
Are the changes in PYY3-36 and active GLP-1 due to weight loss?
|
|
|
Metabolic Surgery in T2DM with BMI ≤ 35 kg/m2
|
|
|
International Diabetes Federation
|
|
|
Take home messages
|
|
|
How Does Obesity Surgery Cause Weight Loss and Cure Type 2 Diabetes?
|
|
Deel deze pagina met collega's en vrienden: